Please login to the form below

Not currently logged in
Email:
Password:

Delay for inhaled hypertension treatment

United Therapeutics has announced it is likely to face regulatory delays for the inhaled version of its hypertension drug Remodulin

United Therapeutics Corp today announced it is likely to face regulatory delays for the inhaled version of its hypertension drug Remodulin because of Food and Drug Administration (FDA) concerns over patient instructions.

The company had expected a decision from the FDA by April 30, but will likely face delays because of questions over instructions for using the nebuliser that delivers the drug.

United Therapeutics is a biotechnology company focused on the development and commercialisation of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. The company already sells the drug as an injection called Remodulin. The inhaled version is called Tyvaso.

"Following our most recent discussion with the FDA, we have agreed to conduct human factors testing to validate that the revised instructions for use (IFU) results in the proper use of the device by a naive user," said President and Chief Operating Officer Roger Jeffs, in a statement. "This relatively small study in normal subjects will test the new IFU in its ability to guide patients to accomplish such tasks as proper device assembly, drug administration, disassembly and cleaning, among other things."

Shares of United Therapeutics sank $2 (or 3 per cent) to $66.28 in pre-market activity.

16th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics